Cost-Effectiveness Analysis of Linezolid, Daptomycin, and Vancomycin in Methicillin-Resistant Staphylococcus aureus: Complicated Skin and Skin Structure Infection Using Bayesian Methods for Evidence Synthesis

Bounthavong, Mark; Zargarzadeh, Amir H.; Hsu, Donald I.; Vanness, David J.

doi:10.1016/j.jval.2010.12.006

Cited by 40 publications

(29 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their study found that total direct costs were lower for daptomycin compared to vancomycin, as a result of the reduced length of stay in hospital and the higher success rates with daptomycin. Similar to the analysis presented here, the findings by Bounthavong et al [26 ]were sensitive to the duration of daptomycin treatment. …”

Section: Discussionsupporting

confidence: 90%

“…Bounthavong et al [26 ]used Bayesian methods for evidence synthesis to generate efficacy and safety parameters for a cost-effectiveness analysis model from the perspective of health-care in the USA. Their study found that total direct costs were lower for daptomycin compared to vancomycin, as a result of the reduced length of stay in hospital and the higher success rates with daptomycin.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Using Daptomycin in Hospitalised Patients with cSSTI Caused by Staphylococcus aureus Has an Impact on Costs

et al. 2013

View full text Add to dashboard Cite

Background: The aim was to assess the cost impact of daptomycin compared to vancomycin treatment in patients hospitalised for complicated skin and soft-tissue infection (cSSTI) with suspected methicillin-resistant Staphylococcus aureus infection in the UK. Methods: A decision model was developed to estimate the costs associated with cSSTI treatment. Data on efficacy, treatment duration and early discharge from published clinical trials were used, with data gaps on standard clinical practice being filled by means of clinician interviews. Results: Total health-care costs per patient were GBP 6,214 and GBP 6,491 for daptomycin and vancomycin, respectively. A sensitivity analysis suggested that modifying the parameters within a reasonable range does not impact on the conclusion that the higher cost of daptomycin is likely to be offset by lower costs of monitoring and hospitalisation. Conclusions: This study demonstrates that daptomycin not only provides an alternative treatment for multiple resistant infections, but may also reduce National Health Service costs.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Using Daptomycin in Hospitalised Patients with cSSTI Caused by Staphylococcus aureus Has an Impact on Costs

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Bounthavong et al carried out a cost effectiveness analysis of linezolid, daptomycin, and vancomycin in MRSA cSSTIs using a decision analytical model based on efficacy and safety parameters 172. The total direct costs of linezolid, daptomycin, and vancomycin were USD $18,057, $20,698, and $23,671, respectively.…”

Section: Cost Effectivenessmentioning

confidence: 99%

Clinical update on linezolid in the treatment of Gram-positive bacterial infections

Gould¹

2012

IDR

View full text Add to dashboard Cite

Gram-positive pathogens are a significant cause of morbidity and mortality in both community and health care settings. Glycopeptides have traditionally been the antibiotics of choice for multiresistant Gram-positive pathogens but there are problems with their use, including the emergence of glycopeptide-resistant strains, tissue penetration, and achieving and monitoring adequate serum levels. Newer antibiotics such as linezolid, a synthetic oxazolidinone, are available for the treatment of resistant Gram-positive bacteria. Linezolid is active against a wide range of Gram-positive bacteria and has been generally available for the treatment of Gram-positive infections since 2000. There are potential problems with linezolid use, including its bacteriostatic action and the relatively high incidence of reported adverse effects, particularly with long-term use. Long-term use may also be complicated by the development of resistance. However, linezolid has been shown to be clinically useful in the treatment of several serious infections where traditionally bacteriocidal agents have been required and many of its adverse effects are reversible on cessation. It has also been shown to be a cost-effective treatment option in several studies, with its high oral bioavailability allowing an early change from intravenous to oral formulations with consequent earlier patient discharge and lower inpatient costs.

show abstract

“…36 More recently, a decision analytic model was developed to evaluate the cost-effectiveness of daptomycin, linezolid, and vancomycin in MRSA cSSTIs using Bayesian methods for evidence synthesis. 37 In this study, linezolid was cost-effective compared to vancomycin or daptomycin in the base-case as well as in most of the sensitivity analyses due primarily to decreased length of stay and decreased total direct costs for cSSTIs. 37 Logman, et al performed a network meta-analysis evaluating the pooled microbiological success rates for linezolid, daptomycin, telavancin, tigecycline, dalbavancin, and vancomycin.…”

Section: Current Approved Gram-positive Agentsmentioning

confidence: 77%

“…37 In this study, linezolid was cost-effective compared to vancomycin or daptomycin in the base-case as well as in most of the sensitivity analyses due primarily to decreased length of stay and decreased total direct costs for cSSTIs. 37 Logman, et al performed a network meta-analysis evaluating the pooled microbiological success rates for linezolid, daptomycin, telavancin, tigecycline, dalbavancin, and vancomycin. 38 The results provided a relative difference in microbiological cure rates using Bayesian meta-analysis techniques in the absence of direct head-to-head trials.…”

Section: Current Approved Gram-positive Agentsmentioning

confidence: 77%

Present and Emerging Therapies for Methicillin-Resistant Staphylococcus aureus Skin and Soft Tissue Infections: Focus on Iclaprim

Bach¹,

Hsu²,

Bounthavong³

2011

Clinical Medicine Reviews in Therapeutics

View full text Add to dashboard Cite

show abstract

Cost-Effectiveness Analysis of Linezolid, Daptomycin, and Vancomycin in Methicillin-Resistant Staphylococcus aureus: Complicated Skin and Skin Structure Infection Using Bayesian Methods for Evidence Synthesis

Abstract: Linezolid and daptomycin are potentially cost-effective based on the assumptions of the DA model; however, linezolid appears to be more cost-effective compared to daptomycin and vancomycin for MRSA cSSSIs.

Cited by 40 publications

References 50 publications

Using Daptomycin in Hospitalised Patients with cSSTI Caused by <b><i>Staphylococcus aureus </i></b>Has an Impact on Costs

Using Daptomycin in Hospitalised Patients with cSSTI Caused by <b><i>Staphylococcus aureus </i></b>Has an Impact on Costs

Clinical update on linezolid in the treatment of Gram-positive bacterial infections

Present and Emerging Therapies for Methicillin-Resistant Staphylococcus aureus Skin and Soft Tissue Infections: Focus on Iclaprim

Contact Info

Product

Resources

About